The present invention relates to the use of novel pyrrolopyrazinyl urea derivatives of Formula I,
wherein the variables R
1
, R
2
, R
3
, R
4
, and R
5
are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.